Novartis’ pioneering cancer gene therapy drug get US panel support

July 17, 2017

A pioneering cancer drug treatment developed by Swiss multinational pharmaceutical company Novartis AG has received support from an advisory panel to the US Food and Drug Administration (FDA), which could lead to the drug becoming the first gene therapy to be approved in the US.

The panel voted 10-0 that the drug, tisagenlecleucel, should be approved to treat patients with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of US childhood cancer.

The FDA is not obliged to follow the recommendations of its advisers but typically does so. The agency is expected to rule on the drug by the end of September.

Approval of tisagenlecleucel would have significant implications not only for Novartis but for companies developing similar treatments, including Kite Pharma Inc., Juno Therapeutics Inc., and bluebird bio Inc.

All four are developing chimeric antigen receptor T-cell therapies (CAR-T), which harness the body’s own immune cells to recognize and attack malignant cells.

If approved, the drugs, which are infused just once, are expected to cost up to US$500,000 and generate billions of dollars for their developers. Success would also help advance a cancer-fighting technique that scientists have been trying to perfect for decades and lift the broader field of cell therapy.

“In the last five years there have been a significant number of cell therapy companies that have gone public or gotten investment in hopes of moving this type of therapy forward,” said Reni Benjamin, an analyst at Raymond James. “This is our first glimpse from a commercial and regulatory perspective about how the FDA is thinking about this space.”

A clinical trial of Novartis’s drug showed that 83% of patients who had relapsed or failed chemotherapy, achieved complete or partial remission three months post infusion. Patients with ALL who fail chemotherapy typically have only a 16% to 30% chance of survival.

Novartis is also testing the drug in diffuse large b-cell Lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, as is Kite. Part of the competitive landscape will include which company is best able to manufacture its product most efficiently and reliably.

The products are made by extracting and isolating a patient’s T cells, genetically engineering them to recognize and target specific cancer cells, and then infusing them back into the patient. Novartis said the entire process will take 22 days by the time it is launched.

A serious complication known as cytokine release syndrome (CRS), which occurs when the body’s immune system goes into overdrive, was experienced by more than half of the patients. Doctors were able to manage the condition and the syndrome caused no deaths.

The FDA also expressed concern that the drug could cause new malignancies over the long term, but panelists generally felt that risk was low.

Tags:

Category: Features, Pharmaceuticals

Comments are closed.

Subscribe to HCA for exclusive updates

Top Viewed News

12 simple steps to a healthy lifestyle

12 simple steps to a healthy lifestyle

Now that the world has returned to normalcy following the pandemic, everyone is back to their daily routines and encounters with stress... Read More

AZBIL: Envisioning the Future of Hospitals

AZBIL: Envisioning the Future of Hospitals

As we strive to be the hospital of choice, why not refine our commitment to excellence beyond the pivotal mission of saving lives?... Read More

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Malaysian researchers at Cancer Research Malaysia (CRMY) and the University of Nottingham Malaysia (UNM) have published... Read More

 Unmasking the Risks of Mercury-Laden Cosmetics

Unmasking the Risks of Mercury-Laden Cosmetics

As the saying goes, beauty is in the eye of the beholder and thus subjective; but in some countries, the ideal of beauty begins... Read More

5 key hospital etiquettes to be mindful of when visiting a sick patient

5 key hospital etiquettes to be mindful of when visiting a sick patient

In moments of illness, the presence of loved ones can comfort and support. However, it’s important for visitors... Read More

Free counters!

2025 – 2026 Exhibitions



2025 Events


9-11 July
Medical Device Development (MEDIX) – Osaka
Makuhari Messe, Japan
www.manufacturing-world.jp


14-16 July
Lab Asia
Kuala Lumpur Convention Centre (KLCC), Malaysia
www.lab-asia.com


16-18 July
Medlab Asia | Asia Health
Malaysia International Trade & Exhibition Centre, Kuala Lumpur
www.medlabasia.com


24 July
Medlab Asia | Asia Health
Singapore
www.conversationaltechsummitasia.com


13-15 August
Philippines Medical
SMX Convention Center Manila Philippines
www.philmedical.com


21-23 August
REHACARE China
Suzhou, China
www.rehacare-c.com


21-23 August
Medical Fair China
Suzhou, China
www.medicalfair.cn


3-5 September
Thailand Lab International
BITEC, Bangkok, Thailand
www.thailandlab.com


3-5 September
Bio Ap International
BITEC, Bangkok
www.bioapinter.com


9-12 September
China Dental Show
National Exhibition and Convention Center (Shanghai)
www.chinadentalshow.com


10-11 September
Hospital Management Asia
Shangri-La Kuala Lumpur, Malaysia
www.hospitalmanagementasia.com


10-12 September
Medical Fair Thailand
BITEC, Bangkok
www.medicalfair-thailand.com


10-12 September
GITEX Digi Health & Biotech Thailand
BITEC, Bangkok
www.www.gitexdigihealth.com


11-13 September
Bio Asia Pacific
BITEC, Bangkok
www.bioasiapacific.com


16-18 September
OSH India
Hall-6, Bombay Exhibition Centre, Goregaon (E)
www.oshindia.com


24-26 September
Medtec China
Shanghai, China
www.en.medtecchina.com


7-9 October
Malaysia Pharma and Healthcare Expo
Kuala Lumpur, Malaysia
www.mphcexpo.com


9-11 October
Medical Japan Tokyo
Makuhari Messe, Japan
www.medical-jpn.jp


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


29-30 October
United Medical Expo
Astana, Kazakhstan
www.umtexpo.com


7-8 November
Eldercare Exhibition and Conference Asia (ELDEX Asia)
Suntex Singapore Exhibition and Convention Centre
www.eldexasia.com


10-12 November
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center
www.saudipharmaexpo.com


10-12 November
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center
www.saudimedlabexpo.com


27-29 November
International Wellness Expo (IWE 2025)
METIC, Malaysia
www.internationalwellnessexpo.com


27-29 November
Vietnam Medi-Pharm
Friendship Cultural Palace , Hanoi
www.vietnammedipharm.vn


2026 Events


9-12 Febuary
Arab Health
Dubai World Trade Centre
www.arabhealthonline.com


15-17 April
Lab Indonesia
Jakarta Convention Center, Jakarta, Indonesia
www.lab-indo.com


28-30 April
SEACare
MITEC, KL
wwww.ea-healthcare.com


6-7 May
HealthTechX Asia
Sands Expo & Convention Centre, Singapore
www.healthtechx-asia.com


4-6 June
International Health Industry Expo
China
www.ihe-china.com


16-18 June
CPhI China
SNIEC, Shanghai, China
www.cphi.com


25-27 June
Medical Taiwan
Taipei Nangang Exhibition Center, Taipei, Taiwan
www.medicaltaiwan.com.tw


9-11 September
Medical Fair Asia
Marina Bay Sands, Singapore
www.medicalfair-asia.com


9-11 September
Medical Manufacturing Asia
Marina Bay Sands, Singapore
www.medmanufacturing-asia.com


1-2 October
GITEX Vietnam
Hanoi
www.gitexasia.com